EGFR and non-small cell lung carcinoma: The present study compared 21 patients with EGFR mutations and concurrent EGFR amplification with 32 patients with EGFR mutations without concurrent EGFR amplification to assess the prognostic value of EGFR amplification in NSCLC–LM patients treated with EGFR-TKIs.